Argentina and Dominican Republic introduce Nirsevimab monoclonal antibody for RSV protection in infants

The province of San Juan in Argentina became the first Argentine jurisdiction to purchase more than 200 doses of the monoclonal antibody Nirsevimab with its own funds. The treatment targets premature babies, infants with low birth weight and children under two with conditions such as congenital heart disease, chronic lung disease, Down syndrome and other high‑risk disorders. A single injection provides protection for the entire respiratory syncytial virus (RSV) season, aiming to cut hospitalizations for bronchiolitis and pneumonia and ease pressure on pediatric intensive‑care beds.

In the Dominican Republic, the Ministry of Health announced the inclusion of Nirsevimab in the national RSV severe‑disease prevention strategy. The rollout begins at the Dr. Robert Reid Cabral Children’s Hospital and will expand from 11 to 21 public facilities. It replaces the earlier Palivizumab programme, which already reached over 3,500 high‑risk newborns. Officials highlighted that Nirsevimab’s one‑dose schedule offers season‑long immunity, reduces clinic visits, and strengthens protection for the country’s most vulnerable children.